Key result
In pentobarbital-anesthetized dogs, CK-3197 produced energy-efficient positive inotropic responses similar to ouabain, increasing LV dP/dt by up to 109% with favorable myocardial oxygen consumption.
Why the study?
Does CK-3197 improve hemodynamic and myocardial energetic parameters compared to ouabain in pentobarbital-anesthetized dogs?
Does CK-3197 improve hemodynamic and myocardial energetic parameters compared to ouabain in pentobarbital-anesthetized dogs?
CK-3197 acts as a selective positive inotropic agent with preload-reducing activity and energy-efficient inotropic responses in a canine model, suggesting potential utility in heart failure.
Energy-efficient inotropy with CK-3197 in dogs merits further study; leaves open applicability to human heart failure.
CK-3197 was developed as a selective positive inotropic agent for the treatment of congestive heart failure. We compared the hemodynamic and myocardial energetic effects of CK-3197 to ouabain in the pentobarbital-anesthetized dog. Fifteen minutes after intravenous (i.v.) administration of CK-3197 (0.1, 0.3, and 1.0 mg/kg) to five dogs, mean left ventricular (LV) dP/dt increased by 24, 68, and 109% and mean arterial pressure (MAP) decreased by 4, 9, and 18%, respectively, from basal values. CK-3197 was 11 times more potent as a positive inotropic agent than as a vasodilator. Heart rate (HR) increased by 5, 14, and 24% after these doses of CK-3197, whereas LV end diastolic pressure (LVEDP) decreased by 4 mm Hg after the highest dose of compound. LV oxygen consumption (MVO2) and stroke MVO2 increased by 9, 25, and 102% and 1, 8, and 58%, respectively, at the peak of the increases in LV dP/dt. Ouabain (0.02 and 0.03 mg/kg, i.v.) increased MAP (12 and 22%), HR (2 and 20%), and LV dP/dt (19 and 36%), with a 14 and 16% increase in LV MVO2 and a 12 and -6% change in stroke MVO2. Thus, CK-3197 is a selective, positive inotropic agent with preload reducing activity in the dog. CK-3197, similar to ouabain, produced energy-efficient positive inotropic responses with either no increase in MVO2 or increases in myocardial oxygen consumption that were less than the expected 1:1 ratio with LV dP/dt. Therefore, CK-3197 may have significant utility in the clinical treatment of congestive heart failure.
No takes yet. Share an insight, caveat, or question.
Greenberg et al. (1991) studied Congestive heart failure (n=5). CK-3197 vs. Ouabain (0.02 and 0.03 mg/kg, i.v.) was evaluated on Hemodynamic and myocardial energetic effects (mean LV dP/dt, MAP, HR, LVEDP, LV MVO2, stroke MVO2). In pentobarbital-anesthetized dogs, CK-3197 produced energy-efficient positive inotropic responses similar to ouabain, increasing LV dP/dt by up to 109% with favorable myocardial oxygen consumption.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: